Clinical-stage, gene-therapy company Genprex (NASDAQ: GNPX) recently reported that positive
preclinical data for the combination of the TUSC2 gene with an anti-PD1
antibody was recorded by its University of Texas MD Anderson Cancer Center
collaborators in a lung cancer treatment study (http://ibn.fm/Uws4i). An article discussing the study
reads, “The results of the study, which analyzed the combination of the TUSC2
gene and anti-PD1 antibody pembrolizumab, were presented in a poster at the
2019 American Association of Cancer Research Meeting. TUCS2 is a tumor
suppressor gene and the active agent in Genprex’s Oncoprex immunogene therapy.
. . . The poster data showed that TUCS2 in combination with checkpoint blockade
was more effective than checkpoint blockade alone in increasing the survival of
mice with human immune cells (humanized mice) that had metastatic lung cancer.
TUCS2 in combination with pembrolizumab demonstrated the ability to
significantly slow tumor growth.”
To view the full article, visit http://ibn.fm/z1GEU
About Genprex Inc.
Genprex Inc. is a clinical-stage, gene-therapy company
developing potentially life-changing technologies for cancer patients, based
upon a unique proprietary technology platform, including Genprex’s initial
product candidate, Oncoprex(TM) immunogene therapy for non-small cell lung
cancer (NSCLC). Genprex’s platform technologies are designed to administer
cancer-fighting genes by encapsulating them into nanoscale, hollow spheres
called nanovesicles, which are then administered intravenously and taken up by
tumor cells where they express proteins that are missing or found in low
quantities. Oncoprex has a multimodal mechanism of action whereby it interrupts
cell signaling pathways that cause replication and proliferation of cancer
cells, re-establishes pathways for apoptosis, or programmed cell death, in
cancer cells and modulates the immune response against cancer cells. Oncoprex
has also been shown to block mechanisms that create drug resistance. For more
information, visit the company’s website at www.Genprex.com.
NOTE TO INVESTORS: The latest news and updates
relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions
and agreements to conference attendance and clinical study results, our news
breaks keep you up-to-date with the day’s top movers. MissionIR is primarily
focused on strategic communications. We have executed countless communications
programs to address the needs of companies ranging from start-ups to
established industry leaders, gaining valuable experience and the expertise
necessary to determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
